General Clinical Chemistry Analyzers and Accessories
Biotium Creatine Phosphokinase2ba6 CF488A conjugate 0.1mgmL
Creatine Phosphokinase2ba6 CF488A conjugate 0.1mgmL
Echelon Biosciences Research Labs MEMBRANE LIPID ARRAYS 2 pack
Membrane Lipid Arrays are 4 x 5 cm hydrophobic membranes that have been spotted with a concentration gradient of eight different biologically important lipids found in cell membranes. They are used to determine the relative degree of binding of your protein of interest towards one or more of these lipids in a simple protein lipid overlay assay. Bound protein is then detected by an antibody against the protein or affinity tag. This item is non returnable
Abcam Ledipasvir, 5A of hepatitis C virus inhibitor, 500UG
MW 889 Da. Ledipasvir is an inhibitor of non-structural protein 5A of hepatitis C virus. It has potent effects against genotypes 1a, 1b, 4a, and 5a in vitro, but has lower activity against genotypes 2a and 3a. Ledipasvir can have additive to synergistic in vitro antiviral activity when combined with other agents.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Daclatasvir (BMS-790052), HCV NS5A protein inhibitor, 50MG
MW 738.9 Da, Purity =97%. Daclatasvir a potent, direct acting, small molecule inhbitor of HCV NS5A protein. It inhbibits replicons expressing a wide range of HCV genotypes with EC₅₀ values in the pM range (9 and 71 pM against the 1b and 2a genotypes, respectively). It also inhibits infection by the JFH-1 genotype 2a virus in cultured cells. Daclatasvir is thought to inhibit relication of the HCV viral genome by affecting the subcellular localization of HCV NS5A and preventing its incorporation into relication complexes. In HCV-infected Huh7 cells, Daclatasvir (1 nM) inhibits viral RNA synthesis and viron assembly. Daclatasvir displays moderate activity against the OAT1B1 (IC₅₀ = 1.5 μM) and OAT1B3 (IC₅₀ = 3.27 μM) organic anion transporters.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Ticagrelor, P2Y12 receptor antagonist, 25MG
MW 522.6 Da, Purity >98%. Reversible antagonist of the platelet purinergic P2Y12 receptor, the main receptor responsible for ADP-induced platelet aggregation. Changes the conformation of the P2Y12 receptor, resulting in reversible, concentration dependent inhibition of the receptor.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Indo x imod, Indoleamine 2,3-dio x ygenase (IDO) inhibitor, 5G
MW 218.25 Da, Purity >95%. Methylated tryptophan which acts as an Indoleamine 2,3-dioxygenase (IDO) inhibitor. Prevents T-cell anergy triggered by dendritic cells overexpressing IDO in mice.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Indo x imod, Indoleamine 2,3-dio x ygenase (IDO) inhibitor, 250MG
MW 218.25 Da, Purity >95%. Methylated tryptophan which acts as an Indoleamine 2,3-dioxygenase (IDO) inhibitor. Prevents T-cell anergy triggered by dendritic cells overexpressing IDO in mice.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Indo x imod, Indoleamine 2,3-dio x ygenase (IDO) inhibitor, 500MG
MW 218.25 Da, Purity >95%. Methylated tryptophan which acts as an Indoleamine 2,3-dioxygenase (IDO) inhibitor. Prevents T-cell anergy triggered by dendritic cells overexpressing IDO in mice.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Ledipasvir, 5A of hepatitis C virus inhibitor, 5MG
MW 889 Da. Ledipasvir is an inhibitor of non-structural protein 5A of hepatitis C virus. It has potent effects against genotypes 1a, 1b, 4a, and 5a in vitro, but has lower activity against genotypes 2a and 3a. Ledipasvir can have additive to synergistic in vitro antiviral activity when combined with other agents.
The product is subject to the following: Abcam Restricted Use Statement
Abcam TW-37, 100MG
MW 573.7 Da, Purity >98%. Small-molecule inhibitor of BCL-2 (Ki = 0.29 μM). Inhibits multiple BCL-2 family members including BCL-XL (Ki = 1.11 μM) and MCL-1 (Ki= 0.26 μM). Binds to the BCL-2 homology domain 3 (BH3) groove of BCL-2. Significant anti-proliferative and pro-apoptotic activity in lymphoma cells.
The product is subject to the following: Abcam Restricted Use Statement
Abcam TW-37, 50MG
MW 573.7 Da, Purity >98%. Small-molecule inhibitor of BCL-2 (Ki = 0.29 μM). Inhibits multiple BCL-2 family members including BCL-XL (Ki = 1.11 μM) and MCL-1 (Ki= 0.26 μM). Binds to the BCL-2 homology domain 3 (BH3) groove of BCL-2. Significant anti-proliferative and pro-apoptotic activity in lymphoma cells.
The product is subject to the following: Abcam Restricted Use Statement
Abcam AZD1480, 5MG
MW 348.76 Da, Purity >98%. Novel, potent and selective small-molecule JAK2 inhibitor (IC₅₀ < 3 nM). It can effectively inhibit tumor angiogenesis and metastasis mediated by STAT3 in stromal cells as well as tumor cells. Also demonstrates >50-fold selectivity for JAK2 over JAK3.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Kifunensine, class I alpha-mannosidase inhibitor, 5MG
MW 232.19 Da. Cell-permeable, potent, selective inhibitor of class I α-mannosidases. (IC₅₀ = 20-50 nM for mung bean α-1,2-mannosidase I). Alkaloid originally isolated from the actinomycete Kitasatosporia kifunense. Used to suppress Endoplasmic Reticulum-Associated Degradation (ERAD) via the inhibition of endoplasmic reticulum-associated mannosidase activity.
The product is subject to the following: Abcam Restricted Use Statement
Abcam Furamidine dihydrochloride, 25MG
MW 304.3 Da, Purity >=98%. A potent, selective and cell-permeable protein arginine methyltransferase 1 (PRMT1) inhibitor (IC₅₀ = 9.4 μM). Displays selectivity over PRMT5, PRMT6 and CARM1 (IC₅₀ values are 166, 283 and >400 μM respectively). Inhibits cell proliferation in leukemia cell lines.
The product is subject to the following: Abcam Restricted Use Statement